- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Latest Advances in CGM Technology: A 5-question Quiz
Continous glucose monitors (CGMs) received a flurry of US Food and Drug Administration (FDA) appprovals in 2018. Since then, the FDA-approved CGMs have benefited from a variety of enhanced features, new applications, and new approvals that promise to further advance the management of diabetes and thus the functioning and quality of life of patients with diabetes.
Take the 5-question quiz below to see what you know about key original CGM approvals and features and the innovations and advances that have been approved since.
1. Which of the following was the first FDA-approved CGM system to include a fully implantable sensor to detect glucose?
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
